Cargolux, Europe's Largest Cargo Airline, to Cease Transporting Disposables

Regulations by 2FIRSTS.ai
Mar.07.2024
Cargolux, Europe's Largest Cargo Airline, to Cease Transporting Disposables
Cargolux Bans Disposable E-cigarettes in Response to Health and Environmental Concerns, Leading the Industry in Sustainable Practices.

According to a report from Wort on March 6th, Cargolux, the Luxembourg-based international cargo airline, has announced that it will cease transporting disposable e-cigarettes. This decision by Cargolux and its subsidiary, Cargolux Italia, is a proactive response to the growing public concern about the harmful effects of such products on health and the environment.

 

Cargolux stated that disposable e-cigarettes pose a significant risk to human health, particularly to the younger generation, "because they are marketed with enticing flavors." Additionally, due to the potential environmental threat they pose, these products have already been banned in other countries, "these devices contain lithium batteries, and since they are not recyclable, improper disposal could result in environmental risks."

 

The company's CEO, Richard Forson, stated that he hopes that this measure will help reduce the supply of these products in the market.

 

This ban reflects Luxembourg International Air Cargo's commitment to the environment, public health, and safety. Through this measure, we hope to help reduce the availability of these products in the market.

 

At the same time, Cargolux also hopes that this initiative will lead other logistics companies to take similar actions. More and more products are now being included in the company's list of items transported on its global network routes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Product | Clear Tank, Airflow Control and Three-Dimension Flavor Labels: RELX Launches Disposable DIVA in South Korea
Product | Clear Tank, Airflow Control and Three-Dimension Flavor Labels: RELX Launches Disposable DIVA in South Korea
RELX has recently launched its disposable e-cigarette, the RELX DIVA, on online channels in South Korea, offering two nicotine strengths of 0.98% and 1.98%. Publicly available information shows the device features a 20 mL e-liquid capacity and is rated for around 30,000 puffs, alongside a 750 mAh rechargeable battery and two power modes—BOOST and ECO—at approximately 16W and 13W, respectively.
Feb.05 by 2FIRSTS.ai
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
Product | 22ml Combined E-Liquid Supply, Rated for 35,000 Puffs: OXBAR Launches the OX35K Open-System Pod Device
The vaping brand OXBAR has recently listed its open-system, refillable pod device OX35K on its official website. The product features a “2ml built-in pod + two 10ml external refill bottles” e-liquid supply structure and supports top refilling, with a claimed puff count of up to 35,000. It is equipped with a 1000mAh built-in battery and offers dual power modes—BOOST and ECO—positioning the device to balance high-puff performance with an open-system form factor.
Jan.13 by 2FIRSTS.ai
Estonia warns of a booming illicit vape market, raising risks for minors and legitimate trade
Estonia warns of a booming illicit vape market, raising risks for minors and legitimate trade
Estonia’s Chamber of Commerce and Industry and the Tax and Customs Board are urging the government to address a thriving illicit vape market that undermines fair competition and makes vapes easily accessible to minors.
Feb.04 by 2FIRSTS.ai
Imperial Brands Forms Global AI Partnership with Capgemini, Reinforcing Artificial Intelligence as Core Infrastructure in the Nicotine Industry
Imperial Brands Forms Global AI Partnership with Capgemini, Reinforcing Artificial Intelligence as Core Infrastructure in the Nicotine Industry
Industry Insight
Feb.19
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11